This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
FAST-Forward is a randomized parallel-group clinical trial evaluating early radiotherapy-related symptoms in breast cancer. The registry identifies the primary endpoint as early side effects measured weekly up to 6 weeks after radiotherapy using the standardized EORTC QLQ-BR23 questionnaire.
| Feature | FAST-Forward |
|---|---|
| Condition | Cancer, Breast |
| Design | Randomized, parallel assignment |
| Masking | None |
| Primary purpose | Treatment |
| Number of arms | 2 |
| Lead sponsor | University Hospital, Ghent |
| Sponsor type | OTHER |
| Intervention | Questionnaire (device) |
| ClinicalTrials.gov | NCT06345534 |
2. Clinical Question
The primary scientific question is whether radiotherapy-related symptoms in the chest/chest wall can be evaluated over the early post-radiotherapy period using standardized patient-reported assessment with the EORTC QLQ-BR23 questionnaire.
Population
Patients with breast cancer.
Intervention
Questionnaire (device).
Comparator
The registry identifies two randomized arms but does not provide additional arm descriptions.
Primary question
Evaluation of radiotherapy-related symptoms weekly up to 6 weeks after radiotherapy.
3. Trial Design
Randomized comparison
The registry describes a two-arm randomized parallel design. Additional treatment-arm details are not reported in the registry record.
Patient-reported symptoms
The primary endpoint evaluates radiotherapy-related symptoms in the chest/chest wall using the EORTC QLQ-BR23 questionnaire.
4. Endpoints
| Endpoint | Time frame | Description |
|---|---|---|
| Early side effects | Weekly up to 6 weeks after radiotherapy | To evaluate radiotherapy-related symptoms in the chest/chest wall weekly up to 6 weeks after radiotherapy, evaluated with the standardized EORTC QLQ-BR23 questionnaire. |
5. Planned Analysis
The ClinicalTrials.gov record does not report posted statistical analyses or trial results. The registry identifies the primary endpoint as a repeated assessment of radiotherapy-related symptoms over time using a standardized questionnaire.
For an endpoint measured repeatedly over several post-treatment time points, a statistical analysis would typically consider both the magnitude of symptom scores and their pattern over time. Depending on the prespecified statistical analysis plan, approaches for repeated measurements may include models that account for within-patient correlation, comparisons of symptom trajectories, or summary measures over the assessment period.
6. Statistical Methodology
Repeated measurements over time
The FAST-Forward primary endpoint collects symptom information weekly up to 6 weeks after radiotherapy. Measurements from the same patient are correlated because they represent repeated observations from one individual rather than independent samples.
A longitudinal analysis asks whether symptom patterns differ between randomized groups over time, rather than examining each weekly measurement as an unrelated comparison.
Patient-reported outcome analysis
The EORTC QLQ-BR23 is a standardized questionnaire designed to quantify breast-cancer-related symptoms and functioning. Statistical interpretation of questionnaire endpoints requires attention to scoring rules, baseline values, missing responses, and clinically meaningful changes.
Randomized comparison
Randomization provides the framework for comparing the treatment groups because assignment is determined by the study design rather than patient characteristics. The validity of the comparison depends on appropriate analysis of all randomized participants according to the prespecified statistical plan.
7. Statistical Methods Explained
Why are symptoms measured weekly?
Repeated weekly measurements allow investigators to evaluate how symptoms evolve after radiotherapy rather than relying on a single snapshot. This can capture differences in timing and duration of symptoms.
Why are repeated measurements statistically different from separate tests?
Multiple observations from one participant are related. Treating each time point as independent can underestimate uncertainty because the same person contributes information repeatedly.
What does the EORTC QLQ-BR23 questionnaire contribute?
It provides a standardized framework for measuring breast-cancer-related symptoms, allowing patient-reported outcomes to be analyzed using predefined scoring methods.
Why does missing questionnaire data matter?
Incomplete questionnaires can affect longitudinal analyses. Statistical methods must account for missing observations according to the assumptions defined in the analysis plan.
Why is randomization important?
Randomization helps balance measured and unmeasured patient characteristics between groups on average, allowing differences in outcomes to be interpreted within the randomized comparison.
8. Limitations
- No posted results: The registry does not currently report statistical analyses or outcome estimates.
- Limited registry detail: Additional details about treatment arms, sample size calculations, analysis populations, and statistical models are not reported.
- Patient-reported outcomes: Questionnaire-based endpoints require careful interpretation of scoring, missing data, and clinically meaningful differences.
- Long follow-up timeline: The primary completion date is 2033-12-31, so mature endpoint analyses are not yet available in the registry record.
9. Why This Trial Matters Statistically
FAST-Forward is a useful statistical teaching example because it illustrates how modern clinical trials analyze outcomes that are measured repeatedly over time rather than only through traditional binary or survival endpoints.
| Concept | How it appears in FAST-Forward |
|---|---|
| Randomization | Randomized parallel-group design |
| Repeated measurements | Weekly symptom assessments up to 6 weeks after radiotherapy |
| Patient-reported outcomes | EORTC QLQ-BR23 questionnaire assessment |
| Longitudinal analysis | Evaluation of symptom patterns over time |
| Missing data considerations | Important for repeated questionnaire completion |
| Clinical interpretation | Separating statistical differences from meaningful symptom changes |
10. Sources
- ClinicalTrials.gov: NCT06345534.
Continue through the Clinical Biostats knowledge graph
Explore additional clinical-trial statistical methods, educational tutorials, and analysis tools.